Data-driven
precision medicine
Bringing the power of data and artificial intelligence to healthcare
With the power of AI, we now have the ability to
-
ACCELERATE
the discovery of novel targets
-
PREDICT
the effectiveness of treatments
-
IDENTIFY
potentially life-saving clinical trials
-
DIAGNOSE
multiple diseases earlier
Explore Tempus
We can assist pharmaceutical and biotech companies with better drug development.
Learn MoreWe have built a proprietary Platform to make data accessible and deploy AI at scale
Learn MoreOur Science
Through our scientific publications and research projects, we are accelerating and transforming personalized patient care.
View All Publications
Nature Biotechnology Study Reveals that Tempus’ xT Platform Increases Cancer Patients’ Personalized Therapeutic Opportunities
Extensive molecular profiling combined with clinical data identifies targeted therapies and clinical trials for a large proportion of cancer patients, and paired tumor/normal plus transcriptome sequencing outperforms tumor-only DNA panel testing.
A Pan-cancer Organoid Platform for Precision Medicine
Showcasing a robust pan-cancer tumor organoid (TO) platform, revealing genomic/transcriptome fidelity of TO culture from >1,000 patients. We demonstrate a neural-network-based high-throughput approach for label-free, light-microscopy-based drug assays capable of predicting patient-specific heterogeneity in drug responses with applicability across solid cancers.
Validation of a Liquid Biopsy Assay with Molecular and Clinical Profiling of Circulating Tumor DNA
Actionable variants would have been missed if only solid tumor or liquid biopsy tests were performed. Thus, we believe that liquid biopsies provide value to patients when used in combination with standard tissue genotyping.
Improving patient care through high quality testing, clinical trial matching, and deep research data that powers scientific discovery
Tempus picks up CRO Highline Sciences as the precision medicine company expands its healthcare ambitions
Fierce Healthcare Senior Editor Heather Landi speaks to Tempus Founder and CEO Eric Lefkofsky about Tempus’ growth and goals for expanding clinical trial access to patients.
READ ARTICLETempus Announces Agreement with Janssen R&D to Leverage AI/ML and Real-World Evidence to Enhance the Discovery and Development of Oncology Therapies
Janssen leverages Tempus’ AI capabilities to jointly create algorithms intended to further patient pre-screening efforts for specific cancer indications for its clinical trial pipeline.
READ PRESS RELEASETempus Announces Open Enrollment for Study in Collaboration with GSK to Evaluate Niraparib in Advanced Solid Tumor Patients with PALB2 Mutations
Tempus launches the PAVO study to evaluate the efficacy and safety of niraparib for patients with advanced or metastatic solid tumors and a germline or somatic PALB2 mutation.
READ PRESS RELEASEThis is data-driven precision medicine
This is the future of healthcare.
